The new urinary and serum biomarkers are discovered and are being investigated. With them we can diagnose acute kidney injury (AKI) faster and more precisely and they also have a significant role in the outcome prediction. Methods: The study included 22 extremely low-birthweight neonates who were hospitalized in the neonatal intensive care units. They were divided into two groups based on serum creatinine (SCr) level-with and without AKI. Detection and quantification of urinary kidney injury molecule-1 (uKIM-1) was done on the third day of life, using commercially available KIM-1 rapid test. Subsequently, measurements were repeated only in subjects who were diagnosed with AKI, at different values of SCr. results: Logistic regression analysis showed that AKI is an independent risk factor for mortality. In a group of neonates with AKI, 50% of neonates administered the KIM-1 rapid test showed positive findings. KIM-1 rapid test was positive in patients with a wide range of SCr levels (range of 78.73-385 µmol/l), but all subjects had oliguria and died in the next 24 h. conclusion: KIM-1 is a significant predictor of death. On the other hand, our study failed to prove that KIM-1 rapid test has any significance for early prediction of AKI.
a cute kidney injury (AKI) occurs in 2.4-56% neonates treated in neonatal intensive care units (NICU). In neonates with AKI, mortality rate ranges from 33% up to 78% (1) (2) (3) (4) . AKI is an independent predictor of mortality in critically ill newborns. It is believed that AKI leads not only to disturbances of homeostasis of fluids and electrolytes, but also, by suppressing systemic inflammatory response, plays a key role in the systemic derangement in multiorgan failure (5, 6) . Infants who survived AKI in neonatal period, often have longterm sequelae that include hypertension, renal tubular acidosis, impared renal growth, and development or chronic renal failure of different degrees (7, 8) .
The criteria for the diagnosis of AKI are based solely on the basis of serum creatinine levels (7) . Serum creatinine (SCr) levels in premature infants cannot be considered as adequate for the diagnosis of AKI due to few reasons: in the first two to 3 d of life SCr levels are a reflection of mother's SCr, after this period SCr levels fall during next few days or even weeks, depending on the gestational age (GA) (9) ; SCr levels do not change drastically until 50% of kidney function is lost; if the glomerular filtration rate is very low, there is a secretion of the SCr (10); SCr levels are influenced by many factors including lean muscle mass, hydration status, GA, etc; in patients on dialysis, SCr is no longer valid marker for evaluation of renal function, because it is dialyzed as well (11) .
In the future, when new biomarkers of AKI (neutrophil gelatinase-associated lipocalin-NGAL, urinary interleukin-18, kidney injury molecule-1 (KIM-1), serum cystatin, etc.) become widely introduced in routine practice, the present definition of AKI will be indisputably expanded and upgraded, that will provide a possibility for early diagnosis of AKI well before SCr levels rise (6) . In the meantime, until early biomarkers of AKI become routinely used, dynamics of SCr must be closely monitored in order to timely diagnose AKI and assess the severity of the disease (12) .
KIM-1 is a type I transmembrane protein and is highly upregulated in the proximal tubule epithelial cells. KIM-1 mRNA and protein are expressed at a low level in normal kidney but are increased in postischemic kidney. KIM-1 is also a tissue and urinary biomarker for nephrotoxicant-induced kidney injury (13, 14) . These cells undergo regeneration after various forms of injury, and shed KIM-1 antigen into urine. KIM-1 plays a role in epithelial adhesion, growth and differentiation. KIM-1 has a role in the process of regeneration after damage to the epithelium and in the removal of dead cells from the tubular lumen by phagocytosis. Injury of renal tubules leads to increased concentration of urinary KIM-1 (15, 16) .
To determine whether urinary KIM-1 (uKIM-1) can be used to detect AKI in extremely low-birth-weight (ELBW) neonates, we used uKIM-1 rapid test. We evaluated prognostic value of this biomarker for prediction of AKI and mortality.
RESULTS

Out of 30
ELBWs that were hospitalized in our NICU during the study period, 8 met the exclusion criteria (prematurely born infants who died in first 72 h or those with congenital Articles malformations of the urinary system), so the final study group involved a total of 22 patients, of which 10 (45%) had AKI.
On average, the diagnosis of AKI was set in 7th day of life (7.1 ± 5.11). In 8 out of 10 (80%) neonates, the diagnosis of AKI was set in the first 7 d of life. The mean value of SCr on the third day of life in a group of patients with AKI was 112.02 ± 28.07 and 95.22 ± 14.64 μmol/l (P = 0.111) in the group of patients without AKI. There were no patients who received renal replacement therapy.
The average increase in SCr levels from the first to third day of life, in neonates who were diagnosed with AKI during the first 7 d of life, was 44.625 ± 18.438 μmol/l, and in neonates without AKI was 22.625 ± 23.82 μmol/l (P = 0.0498). Table 1 shows characteristics of neonates with and without AKI. Neonates with AKI had significantly lower values of Apgar scores (AS) in first (2.1 vs. 3.8; P = 0.03) and fifth minute (4.2 vs. 6.0; P = 0.012) compared to infants without AKI. These two groups of infants did not differ in birth weight (BW), gestational age (GA), and gender. Table 2 shows comorbidities in patients with and without AKI. Neonates with AKI have been more prone to hypernatriemia (80 vs. 33.3%, P = 0.043) and intracranial hemorrhage (100 vs. 33.3%; P = 0.0017) compared to infants without AKI. Half (50%) of the neonates with AKI had oliguria.
All those conditions were diagnosed before the diagnosis of AKI was set. All neonates were intubated and mechanicaly ventilated and received surfactant endotrachealy in the first day of life. Table 3 shows drugs used in both groups of patients, with and without AKI. In comparation to neonates without AKI, neonates with AKI were more often exposed to dopamine (90 vs. 41.6%; P = 0.031), furosemide (100 vs. 8.3%, P = 0.0001) and colomycine (60 vs. 0%; P = 0.0028) before the diagnosis of AKI was set. None of the neonates, from both groups, received nonsteroidal anti-inflammatory drugs. All neonates were initially treated with ampicillin and gentamycin.
In neonates with AKI, mortality rate was significantly higher compared to infants without AKI (80% (8/10) vs. 25% (3/12); P = 0.03).
Logistic regression analysis showed that AKI is an independent risk factor for mortality (OR 12.00, CI 1.581-91.087).
KIM-1 Rapid Test
In a group of neonates with AKI (n = 10), in five (50%) neonates KIM-1 rapid test showed positive findings, and in remaining five (50%) subjects results were negative. In all neonates Table 4 shows the age (days of life) of patients at the time they were diagnosed with AKI, age (days of life) and SCr levels when KIM-1 rapid test have been done, and the final outcome.
In all infants who did not have AKI, results of KIM-1 rapid test on the third day of life were negative. In those patients, SCr values ranged from 60.9 to 110.1 µmol/l.
Mortality was similar between the groups of newborns with AKI, with positive and negative KIM-1 rapid test (5/5 vs. 3/5; P = 0.444).
In the group of neonates with AKI and negative KIM-1 rapid test, one neonate died within 24 h after the diagnosis of AKI was set; four children normalize renal function (but, later in the course of the disease, two infants died due to sepsis with multiorgan dysfunction).
All neonates with AKI and positive KIM-1 rapid test, died within the next 24 h after KIM-1 became positive.
Histopahological Findings
Mean values of histologic injury scores, in all groups, are shown in Table 5 .
DISCUSSION
Critically ill neonates are at great risk to develop AKI because they are often exposed to a number of nephrotoxic drugs and often have infections that lead to multiorgan dysfunction (17, 18) . In critically ill neonates, AKI usually occurs in the first week of life (80.5%) (12) , which was also confirmed in our study (80%).
Neonatal AKI is a serious problem in critically ill neonates and is associated with poor outcome. The mortality is very high, particularly poor prognosis and high mortality rates have neonates with oliguric AKI (19) . In our study, all neonates that had oliguria died.
It was also found that AKI is a predictor of mortality in ELBW neonates. In their study, Askenazi et al. (20) found that any increase in SCr to 88.4 μmol/l was associated with a twofold increase of odds of death. In one prospective study conducted by Mathur et al. (21) , it was found that the incidence of AKI among neonates with sepsis was 26% and that the mortality rate was higher among neonates with AKI compared to those without AKI. Koralkar et al. (12) also confirmed that mortality is significantly higher in neonates with AKI.
Few studies have examined risk factors for AKI in ELBW neonates. In the study of Askenazi et al. (20) , very-low-birthweight neonates with and without AKI did not differ in BW, GA, gender, Apgar score in first and fifth minute or exposure to nephrotoxic drugs (vancomycin, aminoglicozides, and indomethacin), but neonates with AKI had significantly lower serum sodium levels and higher incidence of intraventricular hemorrhage. In our study, the ELBW neonates with AKI had significantly lower values of AS in the first and in the fifth minute, significantly higher incidence of intracranial hemorrhage and significantly more often were treated with inotrope (dopamine), furosemide, and colystine. Colystine is nephrotoxic, and the majority of newborns with AKI had to receive it due to sepsis caused by Acineobacter spp. Due to the presence of contraindications, there were no patients, in neither group, that received nonsteroidal anti-inflammatory drugs (ibuprofen). In other studies, a significantly higher number of neonates with AKI previously received ibuprofen, and therapy with ibuprofen was stressed out as a risk factor for the development of AKI (1).
Aggarwal et al. (22) also found that the incidence of AKI in neonates with AS ≤ 6 in the fifth minute is significantly higher than in controls. In a group of neonates with AS ≤ 6, Gupta et al. (19) found that the incidence of AKI was 47% and mortality was 14.1%. Those findings were confirmed by similar results of other authors (1, 23, 24) . Choker et al. (25) found that neonates with AKI had significantly lower GS and BW than those without AKI.
In our study, infants with AKI more often had hypernatriemia prior diagnosis of AKI. In a study of Stojanović et al. (26) , it was proven that newborns with AKI have significantly higher serum sodium levels in the third and fourth day of life compared to infants without AKI. Low fluid intake, and especially increased insensibile fluid loss in ELBW neonates may rapidly lead to dehydration (and consequently, high serum sodium levels), which is the major cause of neonatal AKI (7, 27) .
Diagnostic criteria of AKI are still based on the increase in the SCr and/or urine output (12, 20) . Unfortunately, it is well known that the SCr is late biomarker for AKI. In our study, it was found that the increase in the SCr in the first 3 d of life was Presence of interstitial edema: 0-no edema; 1-light edema; 2-moderately prominent edema; 3-marked edema. AKI, acute kidney injury.
Articles significantly higher in ELBW neonates who developed AKI in the first week of life. In the study of Choker et al. (25) , that encompassed 34 very preterm infants, AKI was defined as an increase in daily SCr levels above 43 µmol/l on day 1, and/or 21 µmol/l on day 2, and/or 14 µmol/l on day 3, and/or 22 µmol/l on day 4. Larger studies are needed to prove the importance of these data.
The majority of recently published studies have demonstrated that urinary biomarkers (NGAL, KIM-1, and others) can detect infants who are in high-risk group for development of AKI, and that those biomarkers are accurate for prediction of outcome, such as mortality (6, 27) . The ideal biomarker would be the one that would diagnose AKI immediately after the exposure to etiological factors that may lead to kidney damage and one that is independent of the glomerular filtration rate (28, 29) .
Several studies have shown that the concentration of certain urinary biomarkers depends on gestational age and birth weight. Recent studies have shown that immature neonates have higher concentrations of these biomarkers in the urine. This is probably due to the inability of the immature tubules to reabsorb proteins (6, 30, 31) . There are very few studies that have examined these biomarkers in the neonates.
Clinical studies revealed that KIM-1 is highly effective at distinquishing true acute tubular necrosis from other types of renal injury (6, 30) . van Timmeren et al. (32) found induction of tubular KIM-1 expression in various renal diseases, and showed that KIM-1 expression is associated with tubulointerstitial damage, inflammation, and dedifferentiated tubules (which suggest a role for KIM-1 in tubular fibrosis).
Hystopathological kidney analysis was done in eight patients who have died. More severe damage of proximal and distal tubules was detected in patients with AKI and positive KIM-1, and they also had more prominent interstitial edema compared with patients with AKI and negative KIM-1 and patients without AKI.
Most studies indicate that KIM-1 is not as accurate for early prediction of AKI, but it is better for identifying and confirmation of already developed AKI (6, 28) . Two large studies have shown that KIM-1 is an effective new urinary biomarker for the diagnosis of AKI in the first 24 h after kidney injury, especially for the diagnosis of ischemic AKI (15, 16) . Askenazi et al. (6) examined the different urinary biomarkers as predictors of AKI and mortality in very-low-birthweight infants. Mean values of KIM-1 in neonates with AKI were 867 pg/ml, and without AKI were 835 pg/ml. They have not proven the importance of KIM-1 in the prediction of AKI, but they demonstrated that KIM-1 has the potency to predict mortality in preterm neonates hospitalized in NICU (6) .
In another study, Askenazi et al. (6) presented the reference values for KIM-1 in relation to gestational age. For newborn babies, of 26.1-28 wk reference value is 158 (117-212) pg/ml, and for neonates born before 26 gestational weeks 226 (184-277) pg/ml (31) . In our study, we used rapid test to quantify urinary KIM-1 concentration (33) . In all patients who had AKI and positive KIM-1, urinary KIM-1 levels were somewhere between 250-500 pg/ml. It is interesting that the KIM-1 rapid test was positive in patients with a wide range of SCr levels (range of 78.73-385 µmol/l), but all subjects that were positive for KIM-1 and had AKI also had oliguria and died in the next 24 h. This confirms the hypothesis that the KIM-1 in a significant predictor of death (and probably true predictor of acute tubular necrosis). On the other hand, our study failed to prove that KIM-1 rapid test has any significance for early prediction of AKI.
Huang et al. (16) found that the levels of the uKIM-1 are the highest in patients with acute ischemic tubular necrosis. Detected values of uKIM-1 among patients vary widely, and are influenced by the time. In their study, Han et al. (15) found that the sensitivity of uKIM-1 is only 50% immediately after cardiopulmonary bypass. Two other studies have found much greater sensitivity, of more than 90%, when KIM-1 is measured 2 and 6 h after cardiopulmonary bypass. However, it's sensitivity is decreased to 74% after 12 h cardiopulmonary bypass (34, 35) . Larger studies are needed to determine when is the optimal timing for determination and measurement of KIM-1 levels in relation to the exposure to etiological factors that may cause AKI.
Using an animal model of perinatal asphyxia, Stojanovic et al. (36) found that the kidney cystatin C expression was the most intensive 6 h after hypoxic insult and declined over the time, and that the expression of KIM-1 was less intensive, reaching the peak value 48 h after hypoxic event.
In their study, which examined the serum and urinary biomarkers in a group of asphyctic newborns, Sarafidis et al. (30) , failed to document any significance of uKIM-1 for the prediction of AKI following asphyxia.
To our best knowledge, this is the first study that has examined whether uKIM-1 rapid test may predict AKI in extremely low birth weight neonates. In our study, the positive uKIM-1 rapid test has been associated with severe AKI (already developed AKI) and mortality. The number of ELBW neonates included in the study was small, so larger studies are needed to evaluate KIM-1 against different clinical endpoints (such as the need for dialysis, mortality, length of hospital stay, progression to chronic renal failure).
Also, it would be very important to have a tool to differentiate prerenal from renal kidney failure, to predict the course of AKI and to follow the effects of treatment. Most of the investigators in this field, believe that only a combination of biomarkers will have potential to define the cause of AKI and provide enough information for early diagnosis of AKI.
Present knowledge about the role and significance of early urinary biomarkers of kidney injury like NGAL, KIM-1, osteopontin, cystatin C, interleukin-18, and β-2 microglobulin is limited. Askenazi et al. (6) found that values of osteopontin, cystatin C, and β-2 microglobulin are significantly higher in neonates with AKI, and that higher concentrations of KIM-1 and osteopontin may be related with higher mortality risk. Further trials, involving larger samples of patients, are needed to differentiate which combination of biomarkers of kidney injury has the highest power to predict early development of AKI.
